Cybin Inc.(CYBN)Earnings, Financials & Key Ratios
CYBN•AMEX
Price updated Apr 24, 2026
AboutCybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.Show more
- Revenue$0
- EBITDA-$143M-81.6%
- Net Income-$113M-44.9%
- EPS (Diluted)-0.61+93.5%
- ROE-42.76%-0.8%
CYBN Key Insights
Cybin Inc. (CYBN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CYBN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CYBN Price & Volume
Cybin Inc. (CYBN) stock price & volume — 10-year historical chart
Loading chart...
CYBN Growth Metrics
Cybin Inc. (CYBN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-56.81%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-921.18%
Return on Capital
10 Years-340.77%
5 Years-489.46%
3 Years-53.34%
Last Year-54.11%
CYBN Recent Earnings
Cybin Inc. (CYBN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (27%)
Q1 2026Latest
Feb 9, 2026Metric
Actual
Est
EPS
$0.38+28.3%
$0.53
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$1.39-87.8%
$0.74
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$1.10-115.7%
$0.51
Rev
—
—
Q3 2025
Jun 30, 2025Metric
Actual
Est
EPS
$1.02-100.0%
$0.51
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 9, 2026 | $0.38vs $0.53+28.3% | — |
| Q4 2025 | Nov 13, 2025 | $1.39vs $0.74-87.8% | — |
| Q3 2025 | Aug 13, 2025 | $1.10vs $0.51-115.7% | — |
| Q3 2025 | Jun 30, 2025 | $1.02vs $0.51-100.0% | — |
Based on last 12 quarters of dataView full earnings history →
CYBN Peer Comparison
Cybin Inc. (CYBN) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPS | 1.2B | 12.53 | -4.07 | -151.02% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% | ||||
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 SILO | 5.54M | 6.12 | -0.82 | -67.17% | -88.41% | |||
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ENVB | 764.17K | 1.28 | -0.04 | -220.99% | ||||
 MAPS | 67.48M | 0.39 | 21.55 | -5.32% | 0.86% | 1.12% | 0.20 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 |
Compare CYBN vs Peers
Cybin Inc. (CYBN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CYBN Income Statement
Cybin Inc. (CYBN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jul'17 | Jul'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 864K | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | -100% | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 664K | 168K | 251K | 424K | 0 | 0 |
COGS % of Revenue | - | - | - | 76.85% | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 200K▲ 0% | -168K▼ 184.0% | -251K▼ 49.4% | -424K▼ 68.9% | 0▲ 100.0% | 0▲ 0% |
Gross Margin % | - | - | - | 23.15% | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | -184% | -49.4% | -68.92% | 100% | - |
Operating Expenses | 127.22K | 80.52K | 1.94M | 30.72M | 63.84M | 51.52M | 78.84M | 143.15M | 147.45M |
OpEx % of Revenue | - | - | - | 3556.02% | - | - | - | - | - |
Selling, General & Admin | 127.22K | 80.52K | 1.63M | 26.52M | 46.25M | 25.37M | 46.47M | 88.24M | 84.33M |
SG&A % of Revenue | - | - | - | 3069.1% | - | - | - | - | - |
Research & Development | 0 | 0 | 321.6K | 3.3M | 17.59M | 26.14M | 32.36M | 54.91M | 63.12M |
R&D % of Revenue | - | - | - | 381.94% | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | -482K | 0 | 0 | 0 | 0 | 0 |
Operating Income | -127K▲ 0% | -80.52K▲ 36.6% | -1.95M▼ 2326.7% | -31.04M▼ 1488.3% | -63.84M▼ 105.7% | -51.52M▲ 19.3% | -78.84M▼ 53.0% | -143.15M▼ 81.6% | -147.45M▲ 0% |
Operating Margin % | - | - | - | -3592.01% | - | - | - | - | - |
Operating Income Growth % | - | 36.6% | -2326.73% | -1488.28% | -105.7% | 19.3% | -53.03% | -81.58% | - |
EBITDA | -127K | 80.62K | 0 | -30.99M | -63.67M | -51.28M | -78.58M | -142.67M | -147.08M |
EBITDA Margin % | - | - | - | -3586.34% | - | - | - | - | - |
EBITDA Growth % | - | 163.48% | -100% | - | -105.48% | 19.45% | -53.21% | -81.57% | -67.28% |
D&A (Non-Cash Add-back) | 0 | 161.14K | 1.95M | 49K | 168K | 233K | 260K | 475K | 375K |
EBIT | 0 | 0 | -1.95M | -32.21M | -63.84M | -51.52M | -78.84M | -143.15M | -147.45M |
Net Interest Income | 0 | 0 | 0 | 50K | 0 | 603K | 619K | 8.29M | 4.19M |
Interest Income | 0 | 0 | 0 | 60K | 241K | 603K | 619K | 8.29M | 7.1M |
Interest Expense | 0 | 0 | 0 | 10K | 241K | 0 | 0 | 0 | 0 |
Other Income/Expense | 4 | -20K | 9.6K | -1.7M | -3.79M | 4.03M | 756K | 30.01M | 24.53M |
Pretax Income | -127K▲ 0% | -101K▲ 20.5% | -1.94M▼ 1824.8% | -32.22M▼ 1557.4% | -67.63M▼ 109.9% | -47.49M▲ 29.8% | -78.08M▼ 64.4% | -113.14M▼ 44.9% | -122.93M▲ 0% |
Pretax Margin % | - | - | - | -3729.17% | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -127K▲ 0% | -101K▲ 20.5% | -1.94M▼ 1824.8% | -32.22M▼ 1557.4% | -71.42M▼ 121.7% | -40.04M▲ 43.9% | -78.08M▼ 95.0% | -113.14M▼ 44.9% | -122.93M▲ 0% |
Net Margin % | - | - | - | -3729.17% | - | - | - | - | - |
Net Income Growth % | - | 20.47% | -1824.75% | -1557.41% | -121.68% | 43.94% | -95.02% | -44.9% | -56.81% |
Net Income (Continuing) | -127K | -101K | -1.94M | -32.22M | -67.63M | -47.49M | -78.08M | -113.14M | -122.93M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.01▲ 0% | -0.01▲ 21.7% | -0.04▼ 440.3% | -999999.00▼ 2570691416.7% | -0.43▲ 100.0% | -0.22▲ 48.8% | -9.41▼ 4177.3% | -0.61▲ 93.5% | -5.49▲ 0% |
EPS Growth % | - | - | - | -99999900% | 100% | 48.84% | -4177.27% | 93.52% | -921.18% |
EPS (Basic) | -0.01 | -0.01 | -0.05 | -999999.00 | -0.43 | -0.22 | -9.50 | -0.61 | - |
Diluted Shares Outstanding | 13.89M | 13.89M | 49.98M | 10 | 167.29M | 185.43M | 185.43M | 185.43M | 22.4M |
Basic Shares Outstanding | 13.89M | 13.89M | 40.5M | 10 | 167.29M | 185.43M | 185.43M | 185.43M | 22.4M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CYBN Balance Sheet
Cybin Inc. (CYBN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jul'17 | Jul'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 433.08K | 318.38K | 1.64M | 1.64M | 66.48M | 58.35M | 218.54M | 165.97M | 143.65M |
Cash & Short-Term Investments | 432.81K | 314.32K | 1.54M | 1.54M | 64.03M | 53.64M | 208.99M | 135.02M | 118.69M |
Cash Only | 432.81K | 314.32K | 1.54M | 1.54M | 64.03M | 53.64M | 208.99M | 135.02M | 118.69M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 74K | 1.33M | 2.1M | 3.05M | 0 | 5.88M | 4.11M |
Days Sales Outstanding | - | - | - | 561.44 | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | -212K | 1.27M | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | 0 | - | 1.85K | - | - | - |
Other Current Assets | 263 | 4.06K | 0 | 0 | 1.34M | 1.77M | 2.18M | 2.91M | 1.69M |
Total Non-Current Assets | 10K | 90K | 71K | 71K | 25.63M | 25.71M | 83.49M | 92.65M | 67.16M |
Property, Plant & Equipment | 0 | 0 | 0 | 557K | 557K | 491K | 547K | 141K | 82K |
Fixed Asset Turnover | - | - | - | 1.55x | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 23.37M | 23.37M | 22.89M | 47.48M | 51.49M | 36.9M |
Intangible Assets | 0 | 0 | 0 | 1.7M | 1.7M | 2.08M | 35.47M | 41.02M | 30.18M |
Long-Term Investments | 0 | 0 | 71K | 71K | 242K | 242K | 0 | 0 | 0 |
Other Non-Current Assets | 10K | 90K | 0 | -25.63M | -242K | 0 | 0 | 0 | 0 |
Total Assets | 443.08K▲ 0% | 408.38K▼ 7.8% | 1.71M▲ 319.0% | 1.71M▲ 0.0% | 92.11M▲ 5283.5% | 84.06M▼ 8.7% | 302.02M▲ 259.3% | 258.62M▼ 14.4% | 210.81M▲ 0% |
Asset Turnover | - | - | - | 0.50x | - | - | - | - | 0.00x |
Asset Growth % | - | -7.83% | 318.97% | 0% | 5283.52% | -8.74% | 259.28% | -14.37% | 410.47% |
Total Current Liabilities | 150.29K | 13.65K | 263K | 263K | 4.9M | 7.91M | 10.1M | 21.42M | 14.55M |
Accounts Payable | 0 | 0 | 263K | 2.79M | 5.26M | 5.66M | 9.8M | 21.42M | 0 |
Days Payables Outstanding | - | - | - | 1.54K | 11.43K | 8.24K | 8.44K | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 150.29K | 13.65K | 0 | 2.11M | -362K | 2.25M | 291K | 0 | 14.55M |
Current Ratio | 2.88x | 23.32x | 6.24x | 6.24x | 13.57x | 7.38x | 21.65x | 7.75x | 9.87x |
Quick Ratio | 2.88x | 23.32x | 6.24x | 6.24x | 13.61x | 7.22x | 21.65x | 7.75x | 9.87x |
Cash Conversion Cycle | - | - | - | -973.87 | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 1.09M | 1.09M | 5.26M | 0 | 0 | 44.5M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44.5M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 1.09M | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 150.29K | 13.65K | 263K | 263K | 5.99M | 7.91M | 10.1M | 21.42M | 59.05M |
Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 291K | 0 | 44.5M |
Net Debt | -432.81K | -314.32K | -1.54M | -1.54M | -64.03M | -53.64M | -208.99M | -135.02M | -74.19M |
Debt / Equity | - | - | - | - | - | - | 0.00x | - | 0.29x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.30x |
Net Debt / EBITDA | - | -3.90x | - | - | - | - | - | - | 0.50x |
Interest Coverage | - | - | - | -3103.50x | -264.89x | - | - | - | - |
Total Equity | 292.78K▲ 0% | 394.73K▲ 34.8% | 1.45M▲ 266.8% | 1.45M▲ 0.0% | 86.12M▲ 5847.4% | 76.16M▼ 11.6% | 291.93M▲ 283.3% | 237.2M▼ 18.7% | 151.76M▲ 0% |
Equity Growth % | - | 34.82% | 266.84% | 0% | 5847.38% | -11.57% | 283.33% | -18.75% | 460.74% |
Book Value per Share | 0.02 | 0.03 | 0.03 | 144784.07 | 0.51 | 0.41 | 1.57 | 1.28 | 6.77 |
Total Shareholders' Equity | 292.78K | 394.73K | 1.45M | 1.45M | 86.12M | 76.16M | 291.93M | 237.2M | 151.76M |
Common Stock | 420K | 721.38K | 2.19M | 2.19M | 100.68M | 141.45M | 443.88M | 464.36M | 333.15M |
Retained Earnings | -127.22K | -448.75K | -810K | -810K | -33.03M | -100.66M | -226.23M | -339.37M | -266.15M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 64 | 24K | 24K | -366K | 62.53M | -7.23M | 932K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CYBN Cash Flow Statement
Cybin Inc. (CYBN) cash flow — operating, investing & free cash flow history
| Metric | Jul'17 | Jul'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 2.81K | -83.78K | -1.39K | -19.03M | -19.03M | -45.21M | -68.91M | -101.3M | -103.63M |
Operating CF Margin % | - | - | - | -2202.2% | - | - | - | - | - |
Operating CF Growth % | - | -3077.43% | 98.35% | -1373889.02% | 0% | -137.59% | -52.43% | -47.01% | -140.21% |
Net Income | -127.22K | -100.52K | -1.94K | -32.22M | -32.22M | -67.63M | -78.08M | -113.14M | -122.93M |
Depreciation & Amortization | 0 | 0 | 0 | 49K | 49K | 168K | 424K | 475K | 375K |
Stock-Based Compensation | 0 | 0 | 154 | 11.55M | 18.03M | 4.69M | 13.89M | 42.87M | 39.65M |
Deferred Taxes | 0 | 0 | 0 | 898K | 898K | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 20K | 631 | 1.96M | 1.96M | 4.01M | -111K | -21.71M | -20.32M |
Working Capital Changes | 130.03K | -3.26K | -226 | -1.27M | -1.27M | 213K | -5.03M | -9.79M | -416K |
Change in Receivables | 0 | 0 | -178 | -1.49M | -1.49M | -773K | -1.09M | -1.41M | -1.28M |
Change in Inventory | 0 | 0 | 0 | -511K | -511K | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Investing | -10K | -35K | -170 | -1.19M | -1.19M | -770K | 6.92M | -1.97M | -1.95M |
Capital Expenditures | -10K | -35K | 0 | -231K | -231K | -520K | -21 | -1.97M | -1.96M |
CapEx % of Revenue | - | - | - | 26.74% | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | -958K | -958K | 0 | 7.63M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -170 | -96 | 250K | -3.17K | -709.98K | 0 | 10K |
Cash from Financing | 440K | 0 | 5.26K | 82.72M | 35.78M | 35.78M | 254.51M | 20.2M | 75.06M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | -149K | -290K | 44.3M |
Equity Issued (Net) | 0 | 0 | 0 | 1000K | 0 | 1000K | 1000K | 1000K | 2M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 440K | 0 | 5.26K | 6.49M | 35.78M | 362K | 56K | 0 | 149K |
Net Change in Cash | 432.81K▲ 0% | -118.78K▼ 127.4% | 3.71K▲ 103.1% | 62.48M▲ 1684932.4% | 62.48M▲ 0.0% | -10.38M▼ 116.6% | 192.36M▲ 1952.3% | -73.97M▼ 138.5% | -23.48M▲ 0% |
Free Cash Flow | -7.19K▲ 0% | -118.78K▼ 1553.0% | -1.39K▲ 98.8% | -19.26M▼ 1390369.3% | -19.26M▲ 0.0% | -45.73M▼ 137.4% | -69.62M▼ 52.2% | -103.27M▼ 48.3% | -105.59M▲ 0% |
FCF Margin % | - | - | - | -2228.94% | - | - | - | - | - |
FCF Growth % | - | -1553.01% | 98.83% | -1390570.13% | 0% | -137.44% | -52.25% | -48.33% | -22.35% |
FCF per Share | -0.00 | -0.01 | -0.00 | -999999.00 | -0.12 | -0.25 | -0.38 | -0.56 | -4.71 |
FCF Conversion (FCF/Net Income) | -0.02x | 0.83x | 0.00x | 0.59x | 0.27x | 1.13x | 0.88x | 0.90x | 0.86x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CYBN Key Ratios
Cybin Inc. (CYBN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -29.38% | -210.99% | -2225.14% | -163.13% | -49.35% | -42.43% | -42.76% | -81% |
Return on Invested Capital (ROIC) | - | - | - | -435.36% | -173.24% | -111.83% | -115.81% | -115.04% |
Gross Margin | - | - | 23.15% | - | - | - | - | - |
Net Margin | - | - | -3729.17% | - | - | - | - | - |
Debt / Equity | - | - | - | - | - | 0.00x | - | 0.29x |
Interest Coverage | - | - | -3103.50x | -264.89x | - | - | - | - |
FCF Conversion | 0.83x | 0.00x | 0.59x | 0.27x | 1.13x | 0.88x | 0.90x | 0.86x |
Revenue Growth | - | - | - | -100% | - | - | - | - |
Related:CYBN Dividend History·CYBN Revenue History·CYBN Price History·CYBN P/E History·CYBN Financial Ratios·CYBN Institutional Holders
CYBN Frequently Asked Questions
Cybin Inc. (CYBN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cybin Inc. (CYBN) grew revenue by 0.0% over the past year. Growth has been modest.
Cybin Inc. (CYBN) reported a net loss of $122.9M for fiscal year 2025.
Dividend & Returns
Cybin Inc. (CYBN) has a return on equity (ROE) of -42.8%. Negative ROE indicates the company is unprofitable.
Cybin Inc. (CYBN) had negative free cash flow of $105.6M in fiscal year 2025, likely due to heavy capital investments.